Antimicrobial Peptide, LL-37, And Its Potential As An Anti-HIV Agent.
Vera-Cruz. Ana A; Tanphaichitr. Nongnuj N; Angel. Jonathan B JB
Key Findings
- LL-37 can inhibit HIV infection in primary T‑cells in vitro
- It may suppress key HIV enzymes, but its immune effects could also sometimes boost the virus
- LL-37 kills other sexually‑transmitted pathogens and has spermicidal activity, making it a candidate for multipurpose prevention products
Practical Outcomes
- At this stage LL-37 is not a ready‑to‑use supplement or drug for biohackers. The main takeaway is that it’s a promising molecule for future topical HIV/STD prevention gels, but you should wait for clinical trials before trying it. Keep an eye on emerging research for any safe, dosage‑tested formulations.
Summary
LL-37 is a natural antimicrobial peptide that shows some ability to block HIV infection in lab tests and may also affect the virus’s enzymes, but the evidence is still early and mixed. It also kills other sexually‑transmitted germs and can act as a sperm blocker, so it could become a multi‑purpose gel or spray for sexual health, though more research is needed before anyone can use it safely.
Abstract
Human immunodeficiency virus (HIV) continues to have a profound global health impact. New infections continue at a high rate despite the development of prophylactic therapies, prompting the need for development of novel preventative approaches. Antimicrobial peptides (AMPs), such as LL-37, display broad microbicidal properties and have potential as anti-HIV agents. LL-37 has been studied for its anti-HIV activity and the limited data available suggest it can inhibit HIV infection in primary T cells as well as exert inhibitory effects on key HIV enzymes. Its immunomodulatory properties may both enhance and inhibit HIV replication. In addition, LL-37 has both 1) the ability to kill other sexually-transmitted pathogens and 2) spermicidal activity; thus, it is a good candidate for multipurpose prevention technology. Further investigation of its anti-HIV activity is warranted.
Study Information
pubmed
2021
2021-10-03T00:00:00.000Z
10.25011/cim.v44i3.36657
10